| Title |
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
|
|---|---|
| Published in |
OncoTargets and therapy, October 2022
|
| DOI | 10.2147/ott.s329095 |
| Pubmed ID | |
| Authors |
Iacopo Petrini, Giuseppe Giaccone |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 17% |
| Student > Postgraduate | 3 | 13% |
| Unspecified | 2 | 8% |
| Professor | 1 | 4% |
| Student > Bachelor | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 11 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 17% |
| Medicine and Dentistry | 4 | 17% |
| Unspecified | 2 | 8% |
| Business, Management and Accounting | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 12 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2022.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#1,438
of 2,967 outputs
Outputs of similar age
#306,456
of 440,277 outputs
Outputs of similar age from OncoTargets and therapy
#15
of 30 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,277 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.